Medical/Pharmaceuticals
Samsung Biologics recognized for leadership band in water security
- Company receives leadership status and A- rating for efficient water resources management - Recognition reflects Samsung Biologics' commitment to water security and implementing sustainable practices across operations INCHEON, South Korea, Feb. 12, 2025 /PRNewswire/ -- Samsung Biolo...
2025-02-12 20:00
2581
111, Inc. Regains Compliance with NASDAQ Requirement
SHANGHAI, Feb. 11, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, announced today that it has recei...
2025-02-11 21:00
2331
GC Biopharma Shares Research Updates on Rare Disorder Drugs at the WORLD Symposium 2025
YONGIN, South Korea , Feb. 11, 2025 /PRNewswire/ -- GC Biopharma, a South Korean biopharmaceutical company, announced onFeb. 10th that it presented development updates on its LSD (lysosomal storage disorder) pipelines at the WORLD Symposium 2025, held fromFeb. 3rd to 7th, 2025, in San Diego, USA....
2025-02-11 16:40
1940
WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year
* Ranked among the top 1% of companies assessed in the pharmaceutical industry * Recognized as a leader in Green CRDMO, driving innovation for a healthier future * Committed to creating long-term value for all stakeholders SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2...
2025-02-10 17:00
2571
BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed Class 1 innovative therapeutic biological product, BR111 f...
2025-02-10 15:32
2187
Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints
* CBL-514, the world's first investigational drug for large-area localized fat reduction, has demonstrated significant efficacy in its second and the last Phase2b study (CBL-0205) before Phase 3. * 54.2% of participants in the CBL-514 group achieved at least 20% fat volume reduction four week...
2025-02-10 14:15
2202
NUS scientists develop realistic 'micro-gut' model to study the relationship between gut microbes and human diseases
The 3D scalable 'gut-on-a-chip' model enables real-time visualisation of the interactions of gut microbes and the human intestine SINGAPORE, Feb. 10, 2025 /PRNewswire/ -- In a breakthrough for the advanced study of gut health, scientists from theNational University of Singapore (NUS) have develo...
2025-02-10 13:14
2204
CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline
SUZHOU, China, Feb. 9, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that its key product, Cejemly® (sugemalimab), has been included in the Europe...
2025-02-10 12:20
2336
CARsgen's First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4
SHANGHAI, Feb. 9, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first subject treated with an allogeneic BCMA CAR-T therapy d...
2025-02-10 08:29
2860
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
CHENGDU, China, Feb. 7, 2025 /PRNewswire/ -- KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody, trade name: Ka...
2025-02-08 09:14
5054
'The convergence between of AI and the Biology' LG Creates "Next-Generation Protein Structure Prediction AI" for Drug Discovery
SEOUL, South Korea, Feb. 7, 2025 /PRNewswire/ -- On the 5th, LG AI Research signed a joint research agreement at the Global Lounge of LG Science Park in Magok, Gangseo-gu,Seoul, with Prof. Min-Kyung Baek from the school of Biological Sciences at SeoulNational University to develop a "next-generat...
2025-02-07 21:00
4376
GCCL Wins 2025 Asia-Pacific Customer Value Leadership Award by Frost & Sullivan
- GCCL's "One-Stop Lab Solution" sets the industry benchmark with unmatched competitiveness and a dedication to global excellence. - Continuing its growth as a globally recognized leader in clinical sample analysis, driven by customer-centric values. YONGIN, South Korea, Feb. 7, 2025 /...
2025-02-07 09:31
2528
Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC
HONG KONG, Feb. 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) evaluating ivonescimab, its independently developed PD-1/VEGF bispecific antibody. Thi...
2025-02-06 09:28
2490
Argent BioPharma: A Hidden Gem traded Under $12M--Edison Group Report Assigned a $327M Valuation to Its Breakthrough Epilepsy Treatment
PERTH, Australia, Feb. 6, 2025 /PRNewswire/ -- Argent BioPharma (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company brings hope to epilepsy patients. For thousands of patients with refractory epilepsy—commonly referred to as drug-resistant epilepsy—the search for effective trea...
2025-02-06 05:00
2516
Datasea Pre-Announces Second Quarter Revenue of $20.5 Million, up 81% Year-over-Year
Gross Profit achieved a 310% Increase Year-over-Year BEIJING, Feb. 5, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or "the Company"), aNevada-based digital technology company specializing in acoustics high-tech and 5G+AI multimodal digital innovations, today pre-announced that its...
2025-02-05 22:30
3860
Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem
Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026 SYDNEY, Feb. 5, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the World Health Organization (WHO) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xaname...
2025-02-05 22:18
2865
I Peace establishes and offers low immunoreaction risk GMP iPS Cells
Three lines of GMP iPS Cells derived from type O female blood are now offered
as off-the-shelf product
PALO ALTO, Calif., Feb. 5, 2025 /PRNewswire/ -- Leading GMP cell CDMO I
Peace, Inc. (https://ipeace.com/en/
2025-02-05 22:00
2468
From 0 to 100 Trillion: The Rise of Sanyou Bio's Intelligent Molecule Library
SHANGHAI, Feb. 5, 2025 /PRNewswire/ -- In the field of biopharmaceuticals, every technological innovation has the potential to revolutionize treatment strategies. Sanyou Bio's Intelligent Hundred-Trillion Molecule Library (AI-STAL) has emerged from scratch as a shining star, forged through a deca...
2025-02-05 18:00
2113
China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment
TAICHUNG, Feb. 5, 2025 /PRNewswire/ -- Healthcare Expo Taiwan is a professional-oriented exposition involving healthcare, information/communication, technology, biopharmaceutical and medical device industries. Attended by healthcare professionals from all over the world, the Expo showcases the l...
2025-02-05 13:00
2452
Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunol...
2025-02-05 12:28
2524
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 275 media titles]
2025-12-26 12:55The Grand Opening of Dreame Hong Kong Flagship Store Showcases Full Product Lineup
[Picked up by 270 media titles]
2025-12-21 12:42
Fijian and Chinese Scholars Gather to Discuss Bilateral Friendship and the Outlook for APEC 2026
[Picked up by 263 media titles]
2025-12-22 15:56
"Nihao China" App Launches as an All-in-One Solution for International Visitors
[Picked up by 253 media titles]
2025-12-24 17:54